← Back to Search

Metabolic Imaging Agent

Hyperpolarized 13C-Pyruvate Imaging for Chemotherapy-Related Heart Damage (HPCardiotox Trial)

Q: Are there any opportunities for new volunteers to partake in this research endeavor?

<p>Unfortunately, clinicaltrials.gov states that this study is not looking to include any additional participants at present; the trial was initially listed on July 1st 2018 and last updated November 15th 2022. However, there are 2289 other studies in need of patients currently open for enrollment.</p>

Phase < 1

Waitlist Available

Led By Vlad G Zaha, MD, PhD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Plan for treatment as cardiotoxic therapy

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 years

Awards & highlights

HPCardiotox Trial Summary

This trial is looking for early changes in heart cells that may be caused by the chemotherapy drug doxorubicin.

Who is the study for?

This trial is for adults with breast cancer who haven't started or have already completed cardiotoxic therapy. They must be able to use contraception, not have diabetes, metal implants incompatible with MRI, or severe illnesses that could affect study participation. Pregnant women and those with certain blood disorders are excluded.Check my eligibility

What is being tested?

The study aims to detect early signs of heart damage from the chemotherapy drug doxorubicin by using a special type of imaging after injecting hyperpolarized 13C-pyruvate. It will look at changes in heart metabolism as indicators of potential harm from this and similar treatments.See study design

What are the potential side effects?

Potential side effects may include reactions related to the injection such as discomfort or bruising at the injection site, allergic reactions to components of the injected substance, and risks associated with MRI scans like discomfort due to claustrophobia.

HPCardiotox Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My treatment plan includes drugs that may affect my heart.

Select...

I am 18 years old or older.

Select...

I am a male and either surgically sterile or my partner uses birth control.

HPCardiotox Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Detect subclinical anthracycline induced cardiotoxicity using hyperpolarized carbon-13 pyruvate

HPCardiotox Trial Design

2Treatment groups

Experimental Treatment

Group I: Formal StudyExperimental Treatment1 Intervention

Hyperpolarized 13C-pyruvate, is injected into patients before receiving cardiotoxic therapy and immediately after, for a cardiac MRI scan

Group II: Feasibility StudyExperimental Treatment1 Intervention

Hyperpolarized 13C-pyruvate injection, is given to patients after completing cardiotoxic therapy, and again at 1 to 6 six months after the first cardiac MRI scan

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,689 Total Patients Enrolled

22 Trials studying Breast Cancer

6,262 Patients Enrolled for Breast Cancer

Vlad G Zaha, MD, PhDPrincipal InvestigatorAdvanced Imaging Research Center

1 Previous Clinical Trials

128 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities for new volunteers to partake in this research endeavor?

"Unfortunately, clinicaltrials.gov states that this study is not looking to include any additional participants at present; the trial was initially listed on July 1st 2018 and last updated November 15th 2022. However, there are 2289 other studies in need of patients currently open for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity

Vlad Zaha 2018. "Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03685175.

All > Toxicity > Breast Cancer